Grey Matters receives PET scanner
Analysis based on 6 articles · First reported Jul 06, 2026 · Last updated Jul 06, 2026
The delivery of the PET scanning system by Grey Matters Health Inc. is expected to positively impact its stock price as it signifies progress in its U.S. expansion strategy. The increased availability of brain-dedicated PET scans, driven by FDA-approved Alzheimer's treatments from companies like Eisai, Biogen, and Eli Lilly and Company, creates a significant market opportunity for Grey Matters Health Inc. and the broader healthcare sector involved in neurodegenerative disease diagnostics.
Grey Matters Health Inc., a Canadian healthcare company, has taken delivery of its first brain dedicated PET scanning system for its flagship NovaScan Neuroimaging ClinicsTM location in Davie, United States — Florida. This clinic will be the first in the United States to offer brain-only PET scanning for early Alzheimer's detection and other neurodegenerative diseases, utilizing the U.S. FDA-cleared CareMiBrain system. The initiative addresses the growing demand for such diagnostics, especially with the recent FDA approval of monoclonal antibody treatments like Leqembi (from Eisai and Biogen) and Kisunla (from Eli Lilly and Company) for Alzheimer's Disease, which require positive beta-amyloid brain scans for patient authorization and monitoring. Christopher J. Moreau, CEO of Grey Matters Health Inc., highlighted this as a significant milestone for the company's planned network of neuroimaging clinics across the U.S.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard